AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00262522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
Study NCT00262522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
Study NCT00262522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
Study NCT00262522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
Study NCT00788372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
Study NCT01315860 — intervention group
Intervention type: OTHER
Intervention: Postural Analysis
Description: Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
Study NCT03349099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook Flexor
Description: ureteral access sheath
Study NCT03349099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Navigator
Description: ureteral access sheath
Study NCT01656148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Description: Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
Study NCT01656148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fampridine-SR
Description: Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
Study NCT01053871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: conscious sedation using propofol
Study NCT01053871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam with fentanyl
Description: conscious sedation using midazolam with fentanyl
Study NCT00389792 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042
Description: no intervention
Study NCT00389792 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ATI-2042 200 mg
Description: To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
Study NCT01805531 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
Study NCT02639572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siloss® bone graft
Description: The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
Study NCT02639572 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxyapatitie Bone graft
Description: The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
Study NCT04523636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Pre-fabricated or custom resting hand splints
Study NCT01583933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essix retainer
Description: The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake.
Study NCT01583933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hawley retainer
Description: subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
Study NCT03497481 — intervention group
Intervention type: BIOLOGICAL
Intervention: Samples
Description: Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
Study NCT03181230 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02284789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colorado Adult Joint Assessment Evaluation
Description: Physical evaluation of 6 joints, ankles, knees and elbows
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04202679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical
Study NCT04822051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Uncertainty Management Psychoeducation Program
Description: The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
Study NCT00188344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pneumatic dilatation
Description: The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours.
Study NCT00754481 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature \< 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
Study NCT00754481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
Study NCT00290199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter
Description: Foley catheter placed through cervix for cervical ripening
Study NCT00868348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
Study NCT00868348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml infiltration 4 ml intraarticular bolus injection of placebo
Study NCT00255970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA
Description: Demineralized Freeze Dried Allograft bone
Study NCT00255970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regenafil
Description: Demineralized Freeze Dried Bone in a porcine gel carrier
Study NCT00255970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenafil
Description: Demineralized Freeze Dried Bone in a porcine gel carrier
Study NCT02817971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced feedback
Description: Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
Study NCT02817971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard feedback
Description: Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
Study NCT01380379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills and self-defense training
Description: 8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
Study NCT01353040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-6003
Description: Single intravenous administration
Study NCT01353040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous administration
Study NCT03599128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 43.3 mg hydrolyzed green coffee extract
Description: Reconstituted in water and given to subjects
Study NCT03599128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 86.6 mg hydrolyzed green coffee extract
Description: Reconstituted in water and given to subjects
Study NCT03599128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 173 mg hydrolyzed green coffee extract
Description: Reconstituted in water and given to subjects
Study NCT03599128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reconstituted in water and given to subjects
Study NCT01766960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat breakfast will be administered to induce gall bladder emptying.
Study NCT01766960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Five milligrams of intravenous morphine will be administered.
Study NCT00503594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate and temozolomide
Description: Methotrexate and temozolomide
Study NCT00503594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate , procarbazine ,vincristine ,cytarabine
Description: Methotrexate , procarbazine ,vincristine ,cytarabine
Study NCT00102011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: annual screening
Description: Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
Study NCT00102011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fecal occult blood test
Description: Participants undergo a baseline fecal occult blood test (FOBT)
Study NCT00102011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fecal occult blood test
Description: Participants undergo a baseline fecal occult blood test (FOBT)
Study NCT00102011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening colonoscopy
Description: Patients undergo baseline screening colonoscopy
Study NCT00102011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard follow-up care
Description: Standard care
Study NCT00413647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardioPET
Study NCT01708070 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Asthma self-management
Description: Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
Study NCT01708070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma self-management
Description: Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
Study NCT02800889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone
Description: Pixantrone
Study NCT00670436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel eluting PTCA balloon catheter (SeQuent Please)
Description: paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
Study NCT00670436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel eluting Taxus stent (Boston Scientific)
Description: paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
Study NCT00546767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mail and Live Phone
Description: This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
Study NCT00546767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Description: In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
Study NCT00546767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Computer Kiosk
Description: Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
Study NCT00546767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Evaluation Instruments
Description: Evaluation methods typically used in clinical trials
Study NCT03045445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Double Low-Dose protocol CT
Description: Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
Study NCT03045445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol CT
Description: standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA tablet for oral administration
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: TEZ/IVA fixed-dose combination for oral administration.
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: TEZ/IVA fixed-dose combination for oral administration.
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-445
Description: VX-445 tablet for oral administration.
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Matched placebo.
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: Tablet for oral administration.
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: Tablet for oral administration.
Study NCT03227471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-445
Description: VX-445 IV injection
Study NCT04429906 — intervention group
Intervention type: DEVICE
Intervention: Huami smart wearable device
Description: Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group.